|
| Home | Articles | Resources | About us | Quick Tips | Educational materials |
Add this site to your Favorites or Bookmarks. Talk to your doctor The content of Moodletter is for informational purposes only. You should consult with your professional health care provider about your diagnosis and treatment. Moodletter content may not be reprinted without express written permission and credit. ©2006-2012
|
Medication profile:Cymbalta - an SSNRI antidepressant |
Moodletter provides information, hope and help to people living with depression, anxiety or bipolar disorder and those who care for them. Order helpful Mental Health Tip Sheets Buy a pretty pill organizer to help you stay on track with your meds!
|
|||||||||
|
Generic name: duloxetine Cymbalta (Duloxetine)
is one of the newer antidepressants, approved by the FDA in 2004 and manufactured
by Eli Lilly. Duloxetine is in a class of medications called selective
serotonin and norepinephrine reuptake inhibitors (SSNRIs). It offers relief
from both the emotional and painful physical symptoms associated with
depression, according to its maker. It works by increasing the amounts
of serotonin and norepinephrine, natural substances in the brain that
help maintain mental balance. Many antidepressants target only serotonin.
What side effects
can Cymbalta cause? Other most common
side effects included (listed in order of frequency):
Most people were not
bothered enough by these side effects to stop taking Cymbalta, according
to the manufacturer. |
Other possible side effects include the following (Tell your doctor if any of these symptoms are severe or do not go away):
Some side effects, although uncommon, can be serious. If you experience any of them call your doctor immediately. A life-threatening
condition can occur when Cymbalta, and some medicines used to treat migraine
headaches (triptans) are used together. If you take migraine headache
medicines, ask your healthcare professional if your medicine is a triptan.
Related articles Sources: Page updated March 1, 2010
|
||||||||||